NEWARK, Del.—(BUSINESS WIRE)—QPS Holdings, LLC (QPS), a renowned contract research organization (CRO) specializing in bioanalytics and clinical trials, is set to celebrate its 30th anniversary in 2025. Founded by Dr. Benjamin Chien in 1995 to offer high-quality bioanalytical liquid chromatography with tandem mass spectrometry (LC-MS/MS) contract services, QPS has evolved into a global leader in the industry. Starting with a small team in Delaware, USA, the company now boasts over 1,200 employees and operates from eight strategic locations spanning the United States, Europe, Asia, India, and Australia. Additionally, QPS maintains a vast clinical trial network comprising more than 700 sites. Dr. Chien, QPS's founder and CEO, expressed his pride and gratitude for achieving this major milestone. "Thirty years is a significant achievement for QPS, and I am immensely proud of our hardworking and innovative team. Their dedication has been the cornerstone of our success, and I am deeply thankful for their contributions," he said. QPS's impact on the pharmaceutical and biotechnology industries has been profound. The company provides specialized scientific expertise essential for drug development, from preclinical stages to clinical trials. "At QPS, we have equipped our facilities worldwide with state-of-the-art instruments, robust platforms, skilled personnel, and efficient processes to support a wide range of client programs, including those focused on obesity, type 2 diabetes, oncology, central nervous system (CNS) diseases, cell and gene therapy, and other critical areas," Dr. Chien noted. The company's journey from a small molecule bioanalysis shop to a global CRO has seen remarkable growth in both size and service offerings. Today, QPS provides a comprehensive suite of services, including pharmacology, drug metabolism and pharmacokinetics (DMPK), toxicology, bioanalysis, translational medicine, leukopaks, peripheral blood mononuclear cells (PBMCs), cell therapy products, clinical trials, and central laboratory services. This expansion reflects QPS's commitment to meeting the diverse needs of its clients. QPS is distinguished by its emphasis on high-quality data, technical expertise, adherence to study timelines, collaborative problem-solving, and client-centric strategies. The company aims to continue offering tailor-made research services that expedite pharmaceutical breakthroughs worldwide. "Our goal is to maintain our reputation for delivering unparalleled quality and exceptional performance while continuously enhancing our capabilities and resources to better serve our clients," stated Dr. Chien. About QPS Holdings, LLC QPS is a leading global, full-service contract research organization (CRO) that adheres to Good Laboratory Practice (GLP) and Good Clinical Practice (GCP) standards. Since its inception in 1995, the company has transformed from a modest bioanalysis firm into a CRO with a broad spectrum of capabilities. Employing over 1,200 specialists, QPS operates in the United States, Europe, Asia, and Australia, offering advanced services such as pharmacology, DMPK, toxicology, bioanalysis, translational medicine, cell therapy products, clinical trials, and a range of clinical research services. QPS's success is built on a foundation of rigorous quality standards, cutting-edge technical skills, and a flexible, client-focused approach. The company continues to invest in expanding its capacities and resources to uphold its promise of delivering high-quality, reliable, and efficient research services to the global pharmaceutical and biotechnology community. For more information, visit www.qps.com or email [email protected].